Abstract
Men with acute hepatitis B virus (HBV) infection in the Multicenter AIDS Cohort Study from 1985 to 2013 had serological testing to determine proportions with HBV recovery or chronic hepatitis B (CHB). A similar proportion of men without human immunodeficiency virus (HIV) and men with HIV receiving HBV-active antiretroviral therapy (ART) developed CHB [8.2%, 95% confidence interval (CI) 3.8-15.0% vs. 7.7%, 95% CI 2.00-36.0%]. In contrast, 17.5% (95% CI 8.7-29.9%) of men living with HIV, not on HBV-active ART developed CHB. HBV-active ART protects against developing CHB.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 991-993 |
| Number of pages | 3 |
| Journal | AIDS |
| Volume | 35 |
| Issue number | 6 |
| DOIs | |
| State | Published - May 1 2021 |
Funding
We thank the study participants for their time and sample donations and to the MACS project staff at each site. The MACS, now a part of the MACS/WIHS Combined Cohort Study (MWCCS), is supported by the National Institutes of Health. Full Acknowledgements may be found here. This study was also supported by the National Institute of Allergy and Infectious Diseases (R01AI116269 and R03AI096918) CTSI grant UL1TR001881 and an Office of AIDS Research Intramural AIDS Research Fellowship Award. This study was also supported by the National Institute of Allergy and Infectious Diseases (R01AI116269 and R03AI096918) CTSI grant UL1TR001881 and an Office of AIDS Research Intramural AIDS Research Fellowship Award
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy
- Immunology
